SIRT1 overexpression regulates doxorubicin resistance in breast tumor by activating the Akt pathway [30], and SIRT1 promotes tumor growth in colorectal [31], breast [32], and pancreatic cancers [33]. Here, SIRT1 is linked to pancreatic neoplasm.